摘要
Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in chronic liver disease and cirrhosis.The incidence of HCC is growing worldwide.With respect to any other available treatment for liver cancer,liver transplantation (LT) has the highest potential to cure.LTallows for removal at once of both the tumor ("seed")and the damaged-hepatic tissue ("soil") where cancerogenesis and chronic liver disorders have progressed together.The Milan criteria (MC) have been applied worldwide to select patients with HCC for LT,yielding a 4-year survival rate of 75%.These criteria represent the benchmark for patient selection and are the basis for comparison with any other suggested criteria.However,MC are often considered to be too restrictive,and recent data show that between 25% and 50% of patients with HCC are currently transplanted beyond conventional indications.Consequently,any unrestricted expansion of selection criteria will increase the need for donor organs,lengthen waiting periods,increase drop-out rates,and impair outcomes on intention-to-treat analysis.Management of HCC recurrence after LT is challenging.There are a few reports available regarding the safety and efficacy of sorafenib for HCC recurrence after LT,but the data are heterogeneous.A multi-center prospective randomized controlled trial comparing placebo with sorafenib is advised.Alternatively,a metaanalysis of patient survival with sorafenib for HCC recurrence after LT could be helpful to characterize the therapeutic benefit and safety of sorafenib.Here,we review the use of LT for HCC,with particular emphasis on the selection criteria for transplantation in patients with HCC and management of HCC recurrence after LT.
